Patent application number | Description | Published |
20080207567 | Treatment of Hcv Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). | 08-28-2008 |
20090029922 | Use of S1P receptor agonists in heart diseases - The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases. | 01-29-2009 |
20090209495 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER - Provided is a method for treating solid tumors, e.g. tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine- | 08-20-2009 |
20100317627 | Treatment of HCV Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). | 12-16-2010 |
20110124739 | Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the Treatment of Brain Degenerative Diseases - Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases | 05-26-2011 |
20110136739 | Use of S1P Receptor Agonists in Heart Diseases - The invention relates to the use of sphingosine-1-phosphate receptor agonist in the treatment of heart diseases. | 06-09-2011 |
20110306672 | CERAMIDE-ANALOGOUS METABOLITES - This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis. | 12-15-2011 |
20130281541 | USE IN BRAIN DEGENERATIVE DISEASES - Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases. | 10-24-2013 |
20140162964 | USE IN BRAIN DEGENERATIVE DISEASES - Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases. | 06-12-2014 |
20140303257 | Use of EDG Receptor Binding Agents in Cancer - Provided is a method for treating solid tumors, e.g tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent. | 10-09-2014 |